secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2025-06-05T23:59:59+00:00
Accession:  0001628280-25-029639
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics enters $75M ATM equity offering with TD Cowen, terminates prior Oppenheimer facility
--------------------------------------------------------------------------------

- Entered Sales Agreement with TD Cowen for at-the-market offering of up to $75M in common stock.
- Commission to TD Cowen is up to 3% of gross proceeds from sales.
- Terminated prior ATM agreement with Oppenheimer (originally $50M) effective June 4, 2025; no penalties.
- Offering is made under existing effective S-3 registration statement (File No. 333-271225).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828025029639/0001628280-25-029639-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828025029639/avtx-20250603.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-029639

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer